Icodextrin is Associated with a Lower Risk of Stroke in Peritoneal Dialysis Patients

Abstract

Background/Aims: This study investigated whether peritoneal dialysis (PD) patients using icodextrin were at a reduced risk of stroke. Methods: From Taiwan National Health Insurance data, it was found that there were 6,796 new end-stage renal disease patients undergoing dialysis between 2005 and 2011. We compared the risk of stroke between PD patients with or without icodextrin treatment. The follow-up period began from the date of PD initiation to the end of 2011. The time-dependent Cox proportional hazards regression models were used to analyze the risk of stroke. Results: Among PD patients, the icodextrin users had both a lower incidence and risk of stroke than icodextrin non-users (incidence: 22.4 vs. 25.2/1,000 person-years) with an adjusted hazard ratio of 0.76 (95% CI 0.63–0.93). The results were similar in models considering death a competing risk (overall: adjusted subhazard ratio [SHR] 0.78, 95% CI 0.63–0.94). Icodextrin users also had a lower risk of ischemic stroke with or without considering death a competing risk (adjusted SHR 0.71, 95% CI 0.57–0.89 and adjusted HR 0.74, 95% CI 0.59–0.93, respectively), compared to non-users. Conclusion: The use of icodextrin is associated with a lower incidence and risk of stroke in PD patients.

The Effects of Indobufen on Micro-Inflammation and Peritoneal Transport Function in Patients Undergoing Continuous Ambulate Peritoneal Dialysis: A Prospective Randomized Controlled Study

“…The continuous exposure to peritoneal dialysis fluid (PDF) to low or poor biocompatibility can destroy the normal structure and function of the peritoneum, leading to peritoneal dialysis termination. At present, the treatment methods for micro-inflammation mainly include immunomodulatory therapy, anti-fibrosis therapy, traditional peritoneal dialysis catheterization, and protection of the intraperitoneal mesenchymal stem cells (Huddam et al, 2015;Li et al, 2015;Wakabayashi et al, 2015;Raby et al, 2018;Wu et al, 2018;Chiu et al, 2019). Still, further effective and safe drugs need to be developed.…”